Escitalopram updated on 07-01-2025

Urinary malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8218
R25696		 Jordan, 2016 Urinary 3 months or more before pregnancy or1st trimester excluded retrospective cohort (registry) unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 0.73 [0.35;1.54] C
excluded (exposition period) 		7/3,236   1,496/506,155 1,503 3,236
ref
S5890
R14786		 Ban (Controls unexposed, disease free), 2014 Urinary system malformations 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.21 [0.01;3.42] C 0/933   815/325,294 815 933
ref
S6015
R15511		 Jimenez-Solem (Controls unexposed, NOS), 2012 Congenital malformations of the internal urinary system 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.62 [0.04;9.88] C 0/293   2,333/843,797 2,333 293
ref
Total 2 studies 0.36 [0.05;2.58] 3,148 1,226
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ban (Controls unexposed, disease free), 2014Ban, 2014 1 0.21[0.01; 3.42]81593350%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Jimenez-Solem (Controls unexposed, NOS), 2012Jimenez-Solem, 2012 2 0.62[0.04; 9.88]2,33329350%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: critical Total (2 studies) I2 = 0% 0.36[0.05; 2.58]3,1481,2260.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free; 2: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.36[0.05; 2.58]3,1481,2260%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.36[0.05; 2.58]3,1481,2260%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 Tags Adjustment   - No  - No 0.36[0.05; 2.58]3,1481,2260%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 Monotherapy   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.36[0.05; 2.58]3,1481,2260%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 All studiesAll studies 0.36[0.05; 2.58]3,1481,2260%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 20.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.36[0.05; 2.58]3,1481,2260%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 20.510.01.0